---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074514"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:39:09.476316+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioXcel announces publication of non-clinical study on dexmedetomidine in Frontiers in Pharmacology

## Summary
- Study shows dexmedetomidine potently and reversibly regulates stress-mediated behaviors.
- Dexmedetomidine exhibited higher in vitro potency than clonidine, lofexidine, or guanfacine.
- Mitigated responses to acute and repeated stress after both acute and repeated dosing, with no loss of effect.
- No withdrawal effects; no impact on motor function or cognition vs. diazepam or scopolamine.
- Results support BXCL-501's potential for stress-related disorders beyond acute agitation.

## SEC filing metadata
- accession: 0001104659-25-074514
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925074514/0001104659-25-074514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925074514/tm2522638d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074514
- JSON: https://secwatch.observer/filing/0001104659-25-074514.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.